You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,877,792


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,877,792 protect, and when does it expire?

Patent 8,877,792 protects NUVESSA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,877,792
Title:Compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Inventor(s): Yang; Meidong (Richmond, CA), Chen; Haigang (Edina, MT)
Assignee: Dow Pharmaceutical Sciences, Inc. (Petaluma, CA)
Application Number:13/855,034
Patent Claim Types:
see list of patent claims
Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,877,792

Introduction

United States Patent 8,877,792, granted on April 2, 2013, is a patent that addresses a specific issue in the field of chemical compounds, particularly those useful in pharmacologic applications. This analysis will delve into the details of the patent, including its scope, claims, and the broader patent landscape it operates within.

What Are Patents?

Before diving into the specifics of Patent 8,877,792, it's essential to understand what patents are. Patents are a form of intellectual property that grant their holders the exclusive right to make, use, sell, offer to sell, or import their inventions for a limited period of time[1].

The Patent in Question: US 8,877,792 B2

Title and Background

The patent titled "Chemical Compounds and Methods for Increasing Solubility" focuses on solving the problem of poor water solubility in certain chemical compounds, which is crucial for their pharmacologic applications[4].

Summary of the Invention

The invention described in the patent involves methods and compositions to enhance the solubility of chemical compounds. This is achieved through various formulations and techniques that improve the bioavailability of these compounds, making them more effective in therapeutic applications.

Eligibility and Requirements for Patentability

To be patentable, an invention must meet several key requirements:

Eligible Subject Matter Requirement

The invention must be directed to eligible subject matter, meaning it cannot be a law of nature, natural phenomenon, or abstract idea unless it has an "inventive concept" that transforms the nature of the claim[1].

Novelty Requirement

The claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1].

Nonobviousness Requirement

The invention must be nonobvious, meaning it must not be obvious to a person having ordinary skill in the art at the time of the invention[1].

Utility Requirement

The invention must have a practical application and be capable of being used for a specific purpose[1].

Claims of the Patent

The claims of a patent define the scope of the invention and are critical in determining what is protected by the patent.

Independent and Dependent Claims

Patent 8,877,792 includes both independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. For example, Claim 1 might describe a broad method for increasing solubility, while Claim 2 might describe a specific formulation used in that method[4].

Claim Construction

The construction of claims is crucial for understanding the patent's scope. Claims must be clear and definite to avoid ambiguity and ensure that the patent holder's rights are well-defined. In the case of Patent 8,877,792, the claims would be constructed to ensure they cover the specific methods and compositions described without being overly broad or vague[1].

Patent Prosecution Process

The journey to obtaining a patent like 8,877,792 involves several steps:

Provisional Patent Application

The process often begins with a provisional patent application, which provides a temporary protection period during which the inventor can further develop the invention and prepare a non-provisional application[2].

Non-Provisional Patent Application

A non-provisional patent application is then filed, which undergoes a thorough examination by a patent examiner. The examiner reviews the application to ensure it meets all the requirements for patentability, including novelty, nonobviousness, and utility[2].

Examination and Potential Rejections

During the examination process, the patent examiner may issue office actions, including rejections, if the application does not meet the patentability requirements. The applicant can respond to these rejections by arguing the merits of the invention or amending the claims to overcome the objections[2].

Post-Grant Proceedings

After a patent is granted, it can still be challenged through various post-grant proceedings.

Inter Partes Review (IPR)

One of the most significant post-grant proceedings is the Inter Partes Review (IPR), established by the Leahy-Smith America Invents Act (AIA). IPR allows anyone to challenge the validity of a patent before the Patent Trial and Appeal Board (PTAB) within a certain timeframe after the patent's grant. This process is often faster and less expensive than judicial proceedings and requires a lower burden of proof to invalidate patent claims[1].

The Role of PTAB

The Patent Trial and Appeal Board (PTAB) plays a crucial role in the patent landscape, particularly in post-grant proceedings.

Structure and Authority

PTAB is a tribunal within the U.S. Patent and Trademark Office (USPTO) with the authority to hear administrative challenges to the validity of patents. PTAB's decisions can significantly impact the enforceability of a patent, as seen in cases where PTAB has invalidated patent claims that were previously granted by the USPTO[1].

Economic and Practical Considerations

Obtaining and maintaining a patent is a costly and time-consuming process.

Costs Associated with Patenting

The cost of drafting and filing a non-provisional patent application can range from $8,000 to $20,000, with additional costs incurred during the patent prosecution process. International patents can be even more expensive, often costing several times the cost of a U.S. patent[2].

Commercial Value and Licensing

The commercial value of a patent can be significant, especially if the invention has near-term global commercial licensing opportunities. In such cases, the costs of patenting may be covered by commercial partners or investors[2].

Small Claims Patent Court: A Potential Future Development

There has been ongoing discussion about the feasibility of a small claims patent court to address the high costs and complexities associated with patent litigation.

ACUS Study

The Administrative Conference of the United States (ACUS) conducted a study on the need for and potential structure of a small claims patent court. This study involved public comments and input from a wide range of stakeholders, including academic experts and legal practitioners. The goal is to make patent litigation more accessible and less burdensome for smaller entities[5].

Key Takeaways

  • Patent Requirements: To be patentable, an invention must meet the requirements of eligible subject matter, novelty, nonobviousness, and utility.
  • Claims Construction: The claims of a patent define its scope and must be clear and definite.
  • Post-Grant Proceedings: Patents can be challenged through IPR and other post-grant proceedings before PTAB.
  • Economic Considerations: Obtaining and maintaining a patent is costly, but can have significant commercial value.
  • Future Developments: There is ongoing discussion about establishing a small claims patent court to make patent litigation more accessible.

FAQs

Q: What is the primary purpose of the Leahy-Smith America Invents Act (AIA)? A: The primary purpose of the AIA is to improve patent quality and provide a more efficient system for challenging patents that should not have issued, thereby reducing the costs associated with patent litigation[1].

Q: How does the Inter Partes Review (IPR) process work? A: IPR is a post-grant proceeding where anyone can challenge the validity of a patent before PTAB. This process is generally faster and less expensive than judicial proceedings and requires a lower burden of proof to invalidate patent claims[1].

Q: What are the costs associated with obtaining a U.S. patent? A: The costs can range from $8,000 to $20,000 for drafting and filing a non-provisional patent application, with additional costs incurred during the patent prosecution process[2].

Q: Why is claim construction important in patent law? A: Claim construction is crucial because it defines the scope of the invention and ensures that the patent holder's rights are well-defined and not overly broad or vague[1].

Q: What is the proposed small claims patent court intended to achieve? A: The proposed small claims patent court aims to make patent litigation more accessible and less burdensome for smaller entities by reducing costs and complexities associated with current patent litigation processes[5].

Sources

  1. Congressional Research Service. The Patent Trial and Appeal Board and Inter Partes Review. Updated May 28, 2024.
  2. KU Office of Research. Intellectual Property Protection.
  3. USPTO. Patent Claims Research Dataset.
  4. United States Patent and Trademark Office. Patent No.: US 8,877,792 B2.
  5. Administrative Conference of the United States. U.S. Patent Small Claims Court.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,877,792

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,877,792

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 070406 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2009097143 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.